CytoSelect 96-well Cell Transformation Assay

Background: Neoplastic transformation occurs via a series of genetic and epigenetic alterations that yield a cell population that is capable of proliferating independently of both external and internal signals that normally restrain growth. For example, transformed cells show reduced requirements for extracellular growth promoting factors, are not restricted by cell-cell contact, and are often immortal. Anchorage-independent growth is one of the hallmarks of transformation, which is considered the most accurate and stringent in vitro assay for detecting malignant transformation of cells. Traditionally, the soft agar colony formation assay is a common method to monitor anchorage-independent growth, which measures proliferation in a semisolid culture media after 3-4 weeks by manual counting of colonies. Standard soft agar assays are usually performed in 100-mm or 60 mm dishes, where cells are allowed to grow inside a semisolid culture media for 3-4 weeks before sizable colonies appear. This method is quite cumbersome, time-consuming, and difficult when testing a large number of samples. Additionally, the manual counting of colonies is highly subjective; with varying colony sizes, it's difficult to determine meaningful results. CytoSelect™ 96-well Cell Transformation Assay does not involve subjective manual counting of colonies or require a 3-4-week incubation period. Instead, cells are incubated only 6-8 days in a semisolid agar media before being solubilized, lysed and detected by the patented CyQuant GR Dye in a fluorescence plate reader (see Assay Principle below). This format provides a quantitative, high-throughput method to accurately measure cell transformation. Additionally, the short incubation time (6-8 days) makes it possible to assay cells transiently transfected with oncogenes or siRNA. The CytoSelect™ 96-well Cell Transformation Kit provides a robust system for screening oncogenes and cell transformation inhibitors. Each kit provides sufficient quantities to perform 96 tests in a microtiter plate.

1. Shin SI, Freedman VH, Risser R, and Pollack R. (1975) Proc Natl Acad Sci U S A. 72:4435-9.
2. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW and Weinberg RA. (1999) Nature 400:464-8.
1. Maccario, C. et al. (2012).The Resveratrol Analog 4,4'-Dihydroxy-Trans-Stilbene Suppresses Transformation in Normal Mouse Fibroblasts and Inhibits Proliferation and Invasion of Human Breast Cancer Cells. Carcinogenesis. 10.1093/carcin/bgs244.
2. Maag, D. et al. (2011). Inositol Polyphosphate Multikinase is a Physiologic PI3-Kinase that Activates Akt/PKB. PNAS 108:1391-1396.
3. Inami, Y. et al. (2011). Persistent Activation of Nrf2 through p62 in Hepatocellular Carcinoma Cells. J. Cell Biol. 10.1083/jcb.201102031.
4. Rubio, R. et al. (2010). Deficiency in p53 but not retinoblastoma induces the transformation of mesynchymal stem cells in vitro and initiates leiomyosarcoma in vivo. Cancer Res. 70:4185-4194.
5. Faoro, L. et al. (2010). EphA2 Mutation in Lung Squamous Cell Carcinoma Promotes Increased Cell Survival, Cell Invasion, Focal Adhesions, and Mammalian Target of Rapamycin Activation. J. Biol. Chem. 285:18575-18585
6. Iorns, E. et al. (2010). The Role of SATB1 in Breast Cancer Pathogenesis. J.Natl. Cancer Inst. 10.1093/jnci/djq243.
7. Liu, F. et al. (2010). Epigenomic alterations and gene expression profiles in respiratory epithelia exposed to cigarette smoke condensate. Oncogene 29:3650-3664
8. Carnahan, J. (2010). Selective and Potent Raf Inhibitors Paradoxically Stimulate Normal Cell Proliferation and Tumor Growth. Mol. Cancer Ther. 9:2399-2410.
9. Kang, M-I. et al. (2009). A selective small-molecule nuclear factor-kB inhibitor from a high-throughput cell-based assay for "activator protein-1 hits". Mol. Cancer Ther. 8:571-581.
10. Takezawa, K. et al. (2009). Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in RKAS mutant cells. Cancer Res. 69:6515-6521.
11. Lee, K.B. et al. (2008). Low energy proton beam induces tumor cell apoptosis through reactive oxygen species and activation of caspases. Exp. and Mol. Medicine 40(1):118-129.
12. Shen, L. et al. (2008). E1A inhibits the proliferation of human cervical cancer cells (HeLa cells) by apoptosis induction through activation of HER-2/Neu/Caspase-3 pathway. Med. Oncol. 25:222-228.
13. Wei, Q. et al. (2008). Sulfiredoxin is an AP-1 target gene that is required for transformation and shows elevated expression in human skin malignancies. PNAS 105:19738-19743.
14. Gazin, C. et al. (2007). An elaborate pathway required for Ras-mediated epigenetic silencing. Nature 449(7165):1073-1077.

Small volumes of CytoSelect 96-well Cell Transformation Assay assay kit vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS169037 is an assay kit targeting CytoSelect 96-well Cell Transformation Assay.